Cite
HARVARD Citation
Katz, E. et al. (2021). Benefit–Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment‐Resistant Depression. Clinical pharmacology & therapeutics. 109 (2), pp. 536-546. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Katz, E. et al. (2021). Benefit–Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment‐Resistant Depression. Clinical pharmacology & therapeutics. 109 (2), pp. 536-546. [Online].